A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma: Analysis of time to progression

Cancer

Volumn 78, Issue 10, 1996, Pages 2164-2169

  Schellhammer, Paul F ^a   Sharifi, Roohollah ^b   Block, Norman L ^c   Soloway, Mark S ^c   Venner, Peter M ^d   Patterson, A Lynn ^e   Sarosdy, Michael F ^f   Vogelzang, Nicholas J ^g   Chen, Yusong ^h   Kolvenbag, Geert J C M ^h  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d CROSS CANCER INSTITUTE   (Canada)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h ASTRAZENECA   (United Kingdom)

Author keywords

antiandrogen; bicalutamide; combined androgen blockade; flutamide; luteinizing hormone releasing hormone analogue; time to progression

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN; LEUPRORELIN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; DOUBLE-BLIND METHOD; FLUTAMIDE; GOSERELIN; HUMANS; LEUPROLIDE; MALE; PROSTATIC NEOPLASMS;

EID: 10344260143     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19961115)78:10<2164::AID-CNCR18>3.0.CO;2-X     Document Type: Article

References (2)

1. Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL et al. for the Casodex Combination Study Group. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology 1995;45:745-52.
2. Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, et al. for the Casodex Combination Study Group. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Urology 1996;47(Suppl 1A):54-60.